Compare LGI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LGI | ACOG |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.0M | 193.6M |
| IPO Year | N/A | 2024 |
| Metric | LGI | ACOG |
|---|---|---|
| Price | $18.58 | $9.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 32.7K | ★ 130.6K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.32 | $4.50 |
| 52 Week High | $19.88 | $10.14 |
| Indicator | LGI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 65.52 |
| Support Level | $18.32 | $5.28 |
| Resistance Level | $18.71 | N/A |
| Average True Range (ATR) | 0.16 | 0.66 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 68.52 | 78.87 |
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.